These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


444 related items for PubMed ID: 14768052

  • 1. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
    Arancibia-Cárcamo CV, Osawa H, Arnett HA, Háskova Z, George AJ, Ono SJ, Ting JP, Streilein JW.
    Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
    [Abstract] [Full Text] [Related]

  • 2. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA, Leibundgut-Landmann S, Huarte J, Kos-Braun IC, Lavanchy C, Barras E, Borisch B, Steimle V, Acha-Orbea H, Reith W.
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [Abstract] [Full Text] [Related]

  • 3. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [Abstract] [Full Text] [Related]

  • 4. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y, Piskurich JF, Felix NJ, Wang Y, Brickey WJ, Platt JL, Koller BH, Ting JP.
    J Immunol; 1999 Sep 01; 163(5):2425-31. PubMed ID: 10452977
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
    Felix NJ, de Serres S, Meyer AA, Ting JP.
    J Surg Res; 2002 Feb 01; 102(2):185-92. PubMed ID: 11796017
    [Abstract] [Full Text] [Related]

  • 6. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
    Xu Y, McDonald J, Perloff E, Butticè G, Schreiber BM, Smith BD.
    Mol Immunol; 2007 Mar 01; 44(7):1709-21. PubMed ID: 16982097
    [Abstract] [Full Text] [Related]

  • 7. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA.
    Han Y, Zhou ZH, Ransohoff RM.
    J Immunol; 1999 Aug 01; 163(3):1435-40. PubMed ID: 10415044
    [Abstract] [Full Text] [Related]

  • 8. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
    Broxmeyer HE, Cooper S, Hangoc G, Chang CH.
    Exp Hematol; 2006 Aug 01; 34(8):1078-84. PubMed ID: 16863914
    [Abstract] [Full Text] [Related]

  • 9. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo.
    Hobart M, Ramassar V, Goes N, Urmson J, Halloran PF.
    J Immunol; 1997 May 01; 158(9):4260-9. PubMed ID: 9126988
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acute rejection of orthotopic corneal xenografts in mice depends on CD4(+) T cells and self-antigen-presenting cells.
    Tanaka K, Sonoda K, Streilein JW.
    Invest Ophthalmol Vis Sci; 2001 Nov 01; 42(12):2878-84. PubMed ID: 11687532
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M, Song Z, Gorga JC, Ksander B, Ono SJ.
    Invest Ophthalmol Vis Sci; 2004 Sep 01; 45(9):3185-95. PubMed ID: 15326139
    [Abstract] [Full Text] [Related]

  • 14. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene.
    Wojciechowski W, DeSanctis J, Skamene E, Radzioch D.
    J Immunol; 1999 Sep 01; 163(5):2688-96. PubMed ID: 10453010
    [Abstract] [Full Text] [Related]

  • 15. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
    Choi YE, Yu HN, Yoon CH, Bae YS.
    Eur J Immunol; 2009 Mar 01; 39(3):858-68. PubMed ID: 19224634
    [Abstract] [Full Text] [Related]

  • 16. Delayed allograft rejection by the suppression of class II transactivator.
    Kim TW, Choi YM, Seo JN, Kim JH, Suh YH, Chung DH, Jung KC, Oh KI.
    Exp Mol Med; 2006 Jun 30; 38(3):210-6. PubMed ID: 16819279
    [Abstract] [Full Text] [Related]

  • 17. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens.
    Sano Y, Ksander BR, Streilein JW.
    Invest Ophthalmol Vis Sci; 1997 May 30; 38(6):1130-8. PubMed ID: 9152232
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
    Radosevich M, Jager M, Ono SJ.
    Exp Mol Pathol; 2007 Feb 30; 82(1):68-76. PubMed ID: 16650406
    [Abstract] [Full Text] [Related]

  • 19. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
    Shi B, Vinyals A, Alia P, Broceño C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A.
    Int J Biochem Cell Biol; 2006 Feb 30; 38(4):544-62. PubMed ID: 16343978
    [Abstract] [Full Text] [Related]

  • 20. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    Li D, Qian L, Chen C, Shi M, Yu M, Hu M, Song L, Shen B, Guo N.
    J Immunol; 2009 Feb 15; 182(4):1799-809. PubMed ID: 19201831
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 23.